2.0 mg OPT-302

BIOLOGICAL2 trials

Sponsors

Opthea Limited

Conditions

Neovascular Age-related Macular Degeneration

Phase 3

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

TerminatedNCT04757636

Opthea LimitedNeovascular Age-related Macular Degeneration

Start: 2021-03-12End: 2025-03-31Updated: 2025-08-05

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

TerminatedNCT04757610

Opthea LimitedNeovascular Age-related Macular Degeneration

Start: 2021-03-12End: 2025-03-31Updated: 2025-07-22